Malignant neoplasms of thyroid and other endocrine glands
ICD-10 Codes (22)
C74C74.0C74.00C74.01C74.02C74.1C74.10C74.11C74.12C74.9C74.90C74.91C74.92C75C75.0C75.1C75.2C75.3C75.4C75.5C75.8C75.9Updates & Changes
FY 2026 Updates
New Codes (2)
Revised Codes (2)
Deleted Codes
No codes deleted in this range for FY 2026
Historical Changes
- •FY 2025: Routine maintenance updates with minor terminology clarifications
- •FY 2024: Enhanced specificity requirements for certain code ranges
- •FY 2023: Updated documentation guidelines for improved clarity
Upcoming Changes
- •Proposed updates pending review by Coordination and Maintenance Committee
- •Under consideration: Enhanced digital health integration codes
Implementation Guidance
- •Review all FY 2026 updates for C73-C75 codes before implementation
- •Always verify the most current codes in the ICD-10-CM manual
- •Ensure clinical documentation supports the selected diagnosis codes
- +3 more guidance items...
Range Overview
The ICD-10 category C73-C75 covers malignant neoplasms of the thyroid and other endocrine glands. These codes are used to document various types of thyroid and endocrine cancers, including those affecting the adrenal, parathyroid, and pituitary glands. The codes in this range are specific to the type and location of the neoplasm, allowing for accurate documentation and tracking of these serious conditions.
Key Usage Points:
- •C73-C75 codes are used for primary malignant neoplasms only, not secondary or unspecified.
- •Each code specifies the type and location of the neoplasm.
- •Use additional codes to document any associated conditions or complications.
- •C73-C75 codes can be used in any healthcare setting where the patient's condition is documented.
- •Always verify the code in the Tabular List before finalizing.
Coding Guidelines
When to Use:
- ✓When a patient is diagnosed with a primary malignant neoplasm of the thyroid or other endocrine gland.
- ✓When a patient is receiving treatment for a malignant endocrine neoplasm.
- ✓When a patient is being monitored for recurrence of an endocrine cancer.
- ✓When a patient's medical history includes a primary malignant neoplasm of an endocrine gland.
When NOT to Use:
- ✗When the neoplasm is benign or of uncertain behavior.
- ✗When the neoplasm is secondary or unspecified.
- ✗When the patient has a personal history of malignant neoplasm but no current disease.
- ✗When the patient has a neoplasm of an endocrine gland that is not specified as malignant.
Code Exclusions
Always verify exclusions in the Tabular List before finalizing the code.
Documentation Requirements
Documentation for C73-C75 codes should include the type and location of the neoplasm, any associated conditions or complications, and the patient's treatment plan. The documentation should be clear, concise, and specific to support the chosen code.
Clinical Information:
- •Type and location of the neoplasm
- •Associated conditions or complications
- •Treatment plan
- •Patient's response to treatment
- •Prognosis
Supporting Evidence:
- •Pathology reports
- •Imaging studies
- •Operative reports
- •Clinical notes
Good Documentation Example:
Patient diagnosed with primary malignant neoplasm of left adrenal gland. Undergoing chemotherapy with partial response. Plan to continue current treatment regimen.
Poor Documentation Example:
Patient has adrenal cancer.
Common Documentation Errors:
- ⚠Not specifying the type and location of the neoplasm
- ⚠Not documenting associated conditions or complications
- ⚠Not including the patient's treatment plan or response to treatment
Range Statistics
Coding Complexity
Coding for malignant neoplasms of the endocrine glands can be complex due to the need for specific information about the neoplasm and the patient's condition. However, with careful documentation and a thorough understanding of the codes, this complexity can be managed.
Key Factors:
- ▸Determining the specific type and location of the neoplasm
- ▸Documenting associated conditions or complications
- ▸Understanding the patient's treatment plan and response to treatment
- ▸Navigating exclusions and code updates
Specialty Focus
C73-C75 codes are most commonly used by endocrinologists, oncologists, and general surgeons. These specialists diagnose and treat malignant neoplasms of the endocrine glands.
Primary Specialties:
Clinical Scenarios:
- • A patient presenting with a thyroid nodule that is diagnosed as malignant.
- • A patient undergoing chemotherapy for a malignant adrenal neoplasm.
- • A patient being monitored for recurrence of pituitary cancer.
- • A patient with a medical history of parathyroid cancer who is now disease-free.
Resources & References
Resources for C73-C75 codes include the ICD-10 code book, official coding guidelines, and clinical reference materials. These resources can help coders accurately document and code for malignant neoplasms of the endocrine glands.
Official Guidelines:
- ICD-10-CM Official Guidelines for Coding and Reporting
- American Health Information Management Association (AHIMA) Coding Guidelines
- World Health Organization (WHO) ICD-10 Guidelines
Clinical References:
- American Cancer Society
- National Cancer Institute
- American Thyroid Association
Educational Materials:
- AHIMA ICD-10 Training Materials
- WHO ICD-10 Training Materials
- American Academy of Professional Coders (AAPC) ICD-10 Training Materials
Frequently Asked Questions
Can C73-C75 codes be used for benign or unspecified neoplasms?
No, C73-C75 codes are specific to primary malignant neoplasms of the thyroid and other endocrine glands. Benign and unspecified neoplasms have their own codes in other ranges.